The Week in Review: December 5-9

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

Chepko Danil_AdobeStock

This week, Psychiatric TimesTM covered a wide variety of psychiatric issues and industry updates, from ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine. Here are some highlights from the week.

Rolling NDA Submission of Zuranolone for MDD, PPD is Completed

Mary Long_AdobeStock

The rolling submission of a new drug application (NDA) for zuranolone to the US Food and Drug Administration (FDA) has been completed. Zuranolone is an investigational drug by Sage Therapeutics and Biogen that is being evaluated as a potential rapid-acting, once-daily, 14-day, oral short course treatment for major depressive disorder (MDD) and postpartum depression (PPD) in adults. According to data from its LANDSCAPE and NEST development programs, zuranolone has demonstrated rapid and sustained improvement of depressive symptoms, a consistent safety profile, and generally good tolerability. Continue Reading

Meta-Analysis of Intravenous vs Intranasal Ketamine


There is evidence for efficacy of the N-methyl-D-aspartate receptor antagonist ketamine in the treatment of depression. Ketamine produces rapid antidepressant effects, within minutes to hours, that are most pronounced 24 to 48 hours after administration. Ketamine has 2 primary routes of administration: intravenous (IV) and intranasal (IN). The bioavailability for IV ketamine is 100% and 45% to 50% for IN.

In 2019, IN esketamine was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for MDD as well as acute suicidality. By contrast, IV ketamine is considered an off-label treatment for MDD. Continue Reading

Beyond “Bad Behavior”: ADHD in Clinical Practice

Studio Romantic_AdobeStock

Attention-deficit/hyperactivity disorder (ADHD) is a “persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.” It is subclassified into 3 types: combined presentation, predominantly inattentive presentation, and predominantly hyperactive presentation. ADHD is one of the most common neurodevelopmental disorders of childhood, with a prevalence of over 5%.

ADHD is highly heritable (80%), and males are more likely to receive a diagnosis of ADHD. The gender difference is presumably due to higher incidence of impulsive and disruptive behavior in boys, which leads to more frequent referrals. Girls with ADHD, on the other hand, are more frequently described as inattentive. Reasons for misdiagnosis or underdiagnosis link to referral and diagnostic bias, but parents also often tend to rate ADHD symptoms as milder in girls unless accompanied by associated emotional dysregulation (eg, anxiety). Continue Reading

The Case Against New Year’s Resolutions


Making New Year’s resolutions can be helpful for individuals in category No. 1: those who actually follow through with them. But too many individuals—my former self included—find that they are in category No. 2: those who either do not actually use January 1 as a reset or keep up their resolutions for only a few weeks or months. If you are in the second category, here are some ideas to consider.

We often know exactly what changes we should make so we can have better, more fulfilling, more satisfying lives. But unhelpful thoughts sometimes get in the way. Does this sound familiar? “I’m too busy or stressed right now. I’ll wait until January 1st to start exercising/watch what I eat/keep my desk in order/stay in better contact with friends.” The list could go on and on. But what is the harm in putting off making important changes? Continue Reading

See more recent coverage from Psychiatric TimesTM here. And be sure to stay up-to-date by subscribing to the Psychiatric TimesTM E-newsletter.

Do you have a comment on any of these or other articles? Have a good idea for an article and want to write? Interested in sharing your perspectives? Write to us at

Related Videos
View All
© 2023 MJH Life Sciences

All rights reserved.